Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-κB activation

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9163-9168

  Li, Shau Hsuan ^a   Hawthorne, Valerie S ^a   Neal, Christopher L ^a   Sanghera, Sartaj ^a   Xu, Jia ^a   Yang, Jun ^a   Guo, Hua ^a   Steeg, Patricia S ^b   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACUTE-PHASE PROTEINS; ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LIPOCALINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NF-KAPPA B; NITRILES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONES; UP-REGULATION;

EID: 73649125895     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2483     Document Type: Article

References (20)

1. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
2. Dubsky P, Sevelda P, Jakesz R, et al. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res 2008;14: 2082-7.
3. Bohlius J, Weingart O, Trelle S, Engert A. Cancerrelated anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 2006;3:152-64.
4. Fenner MH, Ganser A. Erythropoietin in cancer-related anemia. Curr Opin Oncol 2008;20:685-9.
5. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32.
6. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10: 1033-43.
7. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;52: 595-605.
8. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008;108:389-97.
9. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001;293:829-34.
10. Lin H, Monaco G, Sun T, et al. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene 2005;24:3246-56.
11. Miharada K, Hiroyama T, Sudo K, Danjo I, Nagasawa T, Nakamura Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J Cell Physiol 2008;215:526-37.
12. Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J 2005;19:1881-3.
13. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 1998; 79:565-72.
14. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
15. Palmieri D, Bronder JL, Herring JM, et al. Her-2 over-expression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8.
16. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3æ down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008;68: 1760-7.
17. Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 2009;7: 592-600.
18. Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor êB, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:233-56.
19. La Ferla K, Reimann C, Jelkmann W, Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. FASEB J 2002;16:1811-3.
20. Awada A, Albanell J, Canney PA, et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 2008;98: 1500-7.